Detalles de la búsqueda
1.
Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.
Epilepsy Behav;
61: 63-71, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27315134
2.
Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.
J Clin Psychopharmacol;
35(4): 396-405, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26082975
3.
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
J Clin Psychopharmacol;
32(4): 492-502, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22722508
4.
Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test.
Can J Gastroenterol;
19(6): 350-8, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15997268
5.
Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
CNS Drugs;
28(4): 361-72, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24627301
6.
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
J Opioid Manag;
7(3): 179-92, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21823549
7.
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone.
Pain Physician;
13(6): 561-73, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21102969
8.
A one-year economic evaluation of six alternative strategies in the management of uninvestigated upper gastrointestinal symptoms in Canadian primary care.
Can J Gastroenterol;
24(8): 489-98, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20711528
9.
Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial.
Am J Gastroenterol;
101(9): 2096-106, 2006 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16817845
Resultados
1 -
9
de 9
1
Próxima >
>>